32 / 43
PFS Improvement Regardless of Baseline Liver
Tumor Burden (NETTER 1)
Baseline
Liver Tumor
Burden
Treatment
N Events, n (%)
Median PFS
(months)
Hazard ratio
(95% CI)
P
value
<25%
177
Lu-DOTATATE +
octreotide LAR 30 mg
71
16 (22.5)
28.35
0.218
(0.120‒0.394)
<0.0001
Octreotide LAR 60 mg
70
43 (61.4)
11.04
25%‒50%
177
Lu-DOTATATE +
octreotide LAR 30 mg
27
8 (29.6)
NR
0.202
(0.077‒0.525)
0.001
Octreotide LAR 60 mg
13
9 (69.2)
8.67
>50%
177
Lu-DOTATATE +
octreotide LAR 30 mg
19
6 (31.6)
19.38
0.193
(0.079‒0.474)
0.0003
Octreotide LAR 60 mg
31
26 (83.9)
5.52
•
177
Lu-DOTATATE PRRT was associated with an ~80% reduction in the estimated risk of tumor
progression or death vs octreotide LAR 60 mg, regardless of baseline liver tumor burden
32
Medians are generated using Kaplan‒Meier estimates. HRs, their corresponding 95% CIs, and
P
values are estimated using a Cox regression model with randomized treatment, liver tumor burden at baseline (<25%, 25%‒50%,
or >50%) and (liver tumor burden at baseline*randomized treatment interaction term) as covariates.